Non-competitive N-methyl-D-aspartate antagonists protect against sound-induced seizures in DBA/2 mice
References (53)
The urinary excretion of dextromethorphan and three metabolites in dogs and humans
Toxicol. Appl. Pharmacol.
(1980)- et al.
The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils
Brain Res.
(1988) - et al.
Anticonvulsant action and biochemical effects in DBA/2 mice of CPP (3-((±)-2-carboxypiperazine-4-yl)-propyl-1-phosphonate), a novel N-methyl-D-aspartate antagonist
European J. Pharmacol.
(1987) - et al.
Differential effects of dextrorphan and levorphanol on the excitation of rat spinal neurons by amino acids
European J. Pharmacol.
(1985) - et al.
Systemic administration of MK-801 prevents N-methyl-D-aspartate-induced neuronal degeneration in rat brain
Neurosci. Lett.
(1987) - et al.
Phencyclidine raises kindled seizure thresholds
Pharmacol. Biochem. Behav.
(1982) The NMDA-receptor antagonist, MK-801, suppresses limbic kindling and kindled seizures
Brain Res.
(1988)- et al.
Anticonvulsant properties of phencyclidine-like drugs in mice
European J. Pharmacol.
(1985) - et al.
Quantitative autoradiographic localization of NMDA receptors in rat brain using [3H]CCP: comparison with [3H]TCP binding sites
European J. Pharmacol.
(1987) - et al.
Paradoxical convulsant action of a novel non-competitive N-methyl-D-aspartate (NMDA) antagonist, tiletamine
Brain Res.
(1988)
N-Methyl-D-aspartic acid-induced lethality in mice: selective antagonism by phencyclidine-like drugs
Brain Res.
Anticonvulsant effects of phencyclidine-like drugs: relation to N-methyl-D-aspartic acid antagonism
Brain Res.
Anticonvulsant and antiepileptogenic actions of MK-801 in the kindling and electroshock models
Neuropharmacology
Phencyclidine receptors in rat brain cortex
Biochem. Pharmacol.
Differential effects of competitive and non-competitive N-methyl-D-aspartate antagonists on glucose use in the limbic system
Neurosci. Lett.
The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat
Ann. Neurol.
Antiepileptic and behavioural actions of MK-801 in an animal model of spontaneous absence epilepsy
Epilepsy Res.
Dramatic limbic and cortical effects mediated by high affinity PCP receptors
Life Sci.
The novel anticonvulsant MK-801: a potent and specific ligand of the brain phencyclidine/σ receptor
Brain Res.
Anticonvulsant effects of dextrorphan in rats: Possible involvement in dextromethorphan-induced seizure protection
Life Sci.
Dextromethorphan and carbetapentane: centrally acting non-opioid antitussive agents with novel anticonvulsant properties
Brain Res.
Alterations in local cerebral glucose utilization induce by phencyclidine
Brain Res.
Differential tolerance to repeated daily injections of N-allylnormetazocine and its enantiomers in the rat
Neuropharmacology
NMDA discriminative stimuli are antagonized by competitive NMDA antagonists, PCP-type compounds and kappa agonists
The distribution of [3H]-dextromethorphan binding sites in rat brain differs from that of NMDA sites
Ketamine effects on local cerebral blood flow and metabolism in the rat
J. Cereb. Blood Flow Metab.
Cited by (88)
Sigma-1 receptor and seizures
2023, Pharmacological ResearchWithdrawal Seizures
2017, Models of Seizures and Epilepsy: Second EditionEffects of a non-competitive N-methyl-D-aspartate (NMDA) antagonist, tiletamine, in adult zebrafish
2017, Neurotoxicology and TeratologyCitation Excerpt :Tiletamine (2-(ethylamino)-2-(2-thienyl)-cyclohexanone, or CI-634) is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist chemically related to ketamine and phencyclidine (PCP) (Chapman and Meldrum, 1989; Olney et al., 1989; Rao et al., 1991a).
Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use
2016, Pharmacology and TherapeuticsDextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
2016, Pharmacology and TherapeuticsThe NMDA receptor complex as a therapeutic target in epilepsy: A review
2011, Epilepsy and BehaviorCitation Excerpt :As early as 1965, McCarthy et al. [132] demonstrated in laboratory animals that ketamine is capable of suppressing convulsions induced by electrical stimuli as well as those induced by intravenous infusion of CNS stimulants such as PTZ or caffeine. Since then, many studies reported that ketamine exerted anticonvulsant effects in a variety of animal models of epilepsy including NMDA-, guanidinosuccinate-, p-toluidino-3-propylamino-2-propanol-, mercaptopropionate-, N-(3,5-dimethoxy-4-propoxyphenylethyl)-aziridine-, lidocaine-, picrotoxin-, bicuculline-, strychnine- or PTZ-induced seizures in rodents [133–148]; young chick model of epilepsy [149]; sound-induced convulsions in epilepsy prone rats [150,151]; seizures kindled by repetitive electrical stimulation of the rat motor cortex [152]; kindled amygdaloid seizures in rats [153] and kindling epileptogenesis and seizure expression in developing rats [154]; sound-induced seizures in DBA/2 mice [155]; generalized tonic–clonic seizures induced by metrazol in rats [156]; morphine-induced hind-limb myoclonic seizures [157]; limbic status epilepticus induced by 90 min continuous electrical stimulation of the hippocampus [158]; prolonged status epilepticus in rats and dogs [159,160] and pilocarpine-induced status epilepticus in rats [161]; rat model of partial status epilepticus [162]; electrically precipitated tonic hind-limb extension [163]; MES test in mice [164,165]; and the lithium–pilocarpine seizure model in rats [166]. Infusions of ketamine into the substantia nigra pars reticulata of adult rats also increase the latency of onset to seizures induced by ether flurothyl [167].